Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

C4 Therapeutics, Inc. CCCC

Set alert

Price alert · CCCC

All alert types
3.21 USD -0.16 -4.75%

At close

3.18 -0.03 -0.93%

Pre-market · Nov 3, 5:29 AM ET

Bid
3.20 × 1
Ask
3.21 × 1
3.16 Day range 3.41
1.69 52-week range 5.17
YTD
+68.06%
1 year
+29.44%
Open
3.36
Prev close
3.37
Mkt cap
394.91M
Vol
2.86M
Avg vol
2.43M
EPS
-0.86
P/E
0.00
Div yield
0.00%
More statistics
Low
3.16
High
3.41
Forward P/E
-2.37
Beta
3.06
Short ratio
7.10
Inst. own
91.47%
Dividend
0.00
Ex-div date
Earnings
Aug 1, 2024
50-d avg
5.06
200-d avg
5.96
1y target
15.00

YTD chart

Chart tools
Interval
1m5m15m30m

Signals (45)
NameDateAgo
SMA: BearishNov 2, 202620 hours ago
SMA: BullishOct 30, 20263 days ago
SMA: BearishOct 29, 20264 days ago
SMA: BullishOct 28, 20265 days ago
SMA: BullishOct 27, 20266 days ago
MACD: Buy SignalOct 19, 20262 weeks ago
MACD: Sell SignalOct 14, 20262 weeks ago
SMA: BearishOct 12, 20263 weeks ago
SMA: BullishOct 9, 20263 weeks ago
MACD: Buy SignalOct 9, 20263 weeks ago
SMA: BearishOct 2, 20261 month ago
SMA: BullishSep 28, 20261 month ago
SMA: BearishSep 23, 20261 month ago
RSI: OversoldSep 23, 20261 month ago
SMA: BearishAug 28, 20262 months ago
MACD: Sell SignalAug 28, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago
SMA: BearishJul 15, 20263 months ago
MACD: Sell SignalJul 6, 20263 months ago
MACD: Buy SignalJun 24, 20264 months ago

Newest 20 of 45.

Analyst view

Consensus: buy

Buy
Price target (mean) 15.00 +367.3% upside
Target (low)
4.00
Target (mean)
15.00
Target (high)
39.00
Ratings (0m) 9 6 buy · 3 hold · 0 sell
  • Strong buy1
  • Buy5
  • Hold3
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 9
  • 1 month ago 9
  • 2 months ago 8
  • 3 months ago 8

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

CCCC analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.44-0.59 – -0.26-0.68+35.3%4.33M+32.9%3
Next quarter0.605-0.31 – 1.52-0.37883+259.7%2.50M-17.7%2
Current year-1.36-1.61 – -0.97-2.66+48.8%35.82M+72.6%3
Next year-1.12-1.80 – 0.36-1.36+17.6%38.91M+8.6%4

Upgrades and downgrades

The latest rating changes

CCCC analyst upgrades and downgrades
DateFirmActionFromTo
Dec 19, 2024Wells FargoUpgradeEqual-WeightOverweight
Nov 18, 2024Stephens & Co.Initiated—Equal-Weight
Aug 6, 2024BMO CapitalReiteratedOutperformOutperform
May 9, 2024Wells FargoMaintainedEqual-WeightEqual-Weight
May 9, 2024StifelMaintainedBuyBuy
Feb 26, 2024Morgan StanleyMaintainedEqual-WeightEqual-Weight
Feb 23, 2024StifelReiteratedBuyBuy
Jan 29, 2024JP MorganUpgradeUnderweightNeutral
Dec 13, 2023StifelUpgradeHoldBuy
Nov 6, 2023Morgan StanleyUpgradeUnderweightEqual-Weight
Nov 3, 2023BMO CapitalMaintainedOutperformOutperform
Nov 2, 2023HC Wainwright & Co.MaintainedBuyBuy
Oct 9, 2023B of A SecuritiesMaintainedNeutralNeutral
Aug 9, 2023HC Wainwright & Co.MaintainedBuyBuy
May 30, 2023Evercore ISI GroupMaintained—Outperform
May 12, 2023Morgan StanleyMaintainedUnderweightUnderweight
May 8, 2023HC Wainwright & Co.Maintained—Buy
Mar 28, 2023B of A SecuritiesMaintained—Neutral
Feb 27, 2023Morgan StanleyMaintained—Underweight
Feb 24, 2023HC Wainwright & Co.Reiterated—Buy
Feb 24, 2023JP MorganDowngradeNeutralUnderweight
Jan 3, 2023Wells FargoMaintained—Equal-Weight
Nov 8, 2022Wells FargoMaintained—Equal-Weight
Nov 4, 2022JP MorganDowngradeOverweightNeutral
Oct 11, 2022Morgan StanleyInitiated—Underweight
May 9, 2022HC Wainwright & Co.Maintained—Buy
Apr 28, 2022Credit SuisseInitiated—Underperform
Apr 18, 2022UBSMaintained—Buy
Apr 11, 2022BMO CapitalMaintained—Outperform
Mar 10, 2022JP MorganInitiated—Overweight